Charles River Introduces Global Biotech Incubator Program
Charles River Laboratories (NYSE: CRL) has launched the Charles River Incubator Program (CIP), aimed at supporting early-stage biotechnology companies in the discovery, development, and manufacturing of advanced therapies. Through its Global Innovation Center of Excellence, CIP offers knowledge, connectivity, and priority access to Charles River's extensive portfolio. This initiative builds on the success of the Cell and Gene Therapy Accelerator Program (CAP), designed to assist companies 18-24 months from Investigational New Drug (IND) or Clinical Trial Application (CTA) submission. CIP targets companies 24+ months from IND or CTA submission, providing regulatory and quality expertise, personnel training, and access to laboratory space and equipment. The Global Innovation Center of Excellence integrates a team of scientific, regulatory, and manufacturing experts to foster innovation and support thousands of IND and CTA submissions. The next cohort will be shortlisted at the Cell and Gene Therapy Summit on March 4, 2025, in San Francisco, CA.
Charles River Laboratories (NYSE: CRL) ha lanciato il Charles River Incubator Program (CIP), rivolto a sostenere le aziende di biotecnologia in fase iniziale nella scoperta, sviluppo e produzione di terapie avanzate. Attraverso il suo Global Innovation Center of Excellence, il CIP offre conoscenze, connessioni e accesso prioritario all'ampio portafoglio di Charles River. Questa iniziativa si basa sul successo del Cell and Gene Therapy Accelerator Program (CAP), progettato per assistere le aziende a 18-24 mesi dalla sottomissione dell'Investigational New Drug (IND) o della Clinical Trial Application (CTA). Il CIP si rivolge a aziende con oltre 24 mesi dalla sottomissione dell'IND o della CTA, fornendo competenze in materia di regolamentazione e qualità, formazione del personale e accesso a spazi e attrezzature di laboratorio. Il Global Innovation Center of Excellence integra un team di esperti scientifici, regolatori e di produzione per favorire l'innovazione e supportare migliaia di sottomissioni di IND e CTA. Il prossimo gruppo sarà selezionato al Cell and Gene Therapy Summit il 4 marzo 2025, a San Francisco, CA.
Charles River Laboratories (NYSE: CRL) ha lanzado el Charles River Incubator Program (CIP), con el objetivo de apoyar a las empresas biotecnológicas en etapas tempranas en el descubrimiento, desarrollo y fabricación de terapias avanzadas. A través de su Global Innovation Center of Excellence, el CIP ofrece conocimiento, conectividad y acceso prioritario al amplio portafolio de Charles River. Esta iniciativa se basa en el éxito del Cell and Gene Therapy Accelerator Program (CAP), diseñado para ayudar a las empresas que están a 18-24 meses de la presentación de una Investigational New Drug (IND) o Clinical Trial Application (CTA). El CIP se enfoca en empresas con más de 24 meses desde la presentación de IND o CTA, proporcionando experiencia en regulación y calidad, capacitación del personal y acceso a espacios y equipos de laboratorio. El Global Innovation Center of Excellence integra un equipo de expertos científicos, regulatorios y de fabricación para fomentar la innovación y apoyar miles de presentaciones de IND y CTA. La próxima cohorte se seleccionará en la Cumbre de Terapia Celular y Genética el 4 de marzo de 2025, en San Francisco, CA.
찰스 리버 연구소(Charles River Laboratories)(NYSE: CRL)가 조기 단계의 생명공학 회사를 지원하기 위한 찰스 리버 인큐베이터 프로그램(CIP)을 출시했습니다. 이 프로그램은 고급 요법의 발견, 개발 및 제조에 초점을 맞추고 있습니다. 글로벌 혁신 센터를 통해 CIP는 지식, 연결 및 찰스 리버의 방대한 포트폴리오에 대한 우선 접근을 제공합니다. 이 이니셔티브는 임상 시험 신청(CTA) 또는 임상 시험(IND) 제출로부터 18-24개월 차의 기업을 지원하기 위해 설계된 세포 및 유전자 치료 가속기 프로그램(CAP)의 성공을 기반으로 합니다. CIP는 IND 또는 CTA 제출로부터 24개월 이상 경과한 기업을 대상으로 하며, 규제 및 품질 전문성, 인력 교육, 실험실 공간 및 장비에 대한 접근을 제공합니다. 글로벌 혁신 센터는 혁신을 촉진하고 수천 건의 IND 및 CTA 제출을 지원하기 위해 과학, 규제 및 제조 전문가 팀을 통합합니다. 다음 그룹은 2025년 3월 4일 샌프란시스코, CA에서 열리는 세포 및 유전자 치료 정상 회의에서 선정될 예정입니다.
Charles River Laboratories (NYSE: CRL) a lancé le Charles River Incubator Program (CIP), visant à soutenir les entreprises de biotechnologie en phase précoce dans la découverte, le développement et la fabrication de thérapies avancées. Grâce à son Global Innovation Center of Excellence, le CIP offre des connaissances, des connexions et un accès prioritaire au vaste portefeuille de Charles River. Cette initiative s'appuie sur le succès du Cell and Gene Therapy Accelerator Program (CAP), conçu pour aider les entreprises à 18-24 mois de la soumission d'un Investigational New Drug (IND) ou d'une Clinical Trial Application (CTA). Le CIP cible les entreprises à plus de 24 mois de la soumission de l'IND ou de la CTA, fournissant une expertise réglementaire et qualité, une formation pour le personnel et un accès à des espaces et équipements de laboratoire. Le Global Innovation Center of Excellence intègre une équipe d'experts scientifiques, réglementaires et de fabrication pour favoriser l'innovation et soutenir des milliers de soumissions d'IND et de CTA. Le prochain groupe sera sélectionné lors du Cell and Gene Therapy Summit le 4 mars 2025 à San Francisco, CA.
Charles River Laboratories (NYSE: CRL) hat das Charles River Incubator Program (CIP) ins Leben gerufen, das darauf abzielt, Biotechnologieunternehmen in der Frühphase bei der Entdeckung, Entwicklung und Herstellung von fortschrittlichen Therapien zu unterstützen. Über das Global Innovation Center of Excellence bietet CIP Wissen, Vernetzung und prioritären Zugang zu dem umfangreichen Portfolio von Charles River. Diese Initiative baut auf dem Erfolg des Cell and Gene Therapy Accelerator Program (CAP) auf, das dafür konzipiert wurde, Unternehmen zu unterstützen, die sich 18-24 Monate vor der Einreichung eines Investigational New Drug (IND) oder Clinical Trial Application (CTA) befinden. CIP richtet sich an Unternehmen, die mehr als 24 Monate von IND oder CTA entfernt sind, und bietet Expertise in regulatorischen und qualitativen Fragen, Schulungen für das Personal sowie Zugang zu Laborräumen und -geräten. Das Global Innovation Center of Excellence vereint ein Team von wissenschaftlichen, regulatorischen und herstellenden Experten, um Innovation zu fördern und Tausende von IND- und CTA-Einreichungen zu unterstützen. Die nächste Kohorte wird am 4. März 2025 beim Cell and Gene Therapy Summit in San Francisco, CA, ausgewählt.
- Launch of CIP to support early-stage biotech companies.
- Priority access to Charles River's extensive portfolio.
- Integration with Global Innovation Center of Excellence.
- Support for thousands of IND and CTA submissions.
- None.
Program offers biotechnology developers access to extensive scientific expertise and a wide ecosystem of discovery, development and manufacturing capabilities
“The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offering knowledge, connectivity, and priority access to the Charles River portfolio,” said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River.
Building on the success of the Company’s established global Cell and Gene Therapy (CGT) Accelerator Program (CAP), the CIP focuses on nurturing innovative start-up and early-stage biotechnology companies. The objective of the CIP is to form a strong foundation for commercial viability as its participants gain momentum with the goal of imparting cost-effective, consultative regulatory and quality expertise, personnel training initiatives, and enabling access to laboratory space and equipment. Developers are invited to apply to be part of the next cohort today:
- CIP – Incubates biotechnology developers in the discovery phase, 24+ months from Investigational New Drug (IND) or Clinical Trial Application (CTA) submission.
- CAP – Accelerates advanced therapy developers 18-24 months from IND or CTA submission.
Leveraging a Concept to Cure Portfolio
The CIP and CAP are reinforced by the Company’s Global Innovation Center of Excellence (CoE), strategically positioned and fully integrated at the heart of Charles River’s extensive virtual and physical network. The Global Innovation CoE amalgamates a cross-functional team of scientific, regulatory and manufacturing experts in:
- Drug Discovery
- Safety Assessment
- Research Models
- Clinical to Commercial Contract Development and Manufacturing
- Microbial Solutions
Based out of the Company’s contract development and manufacturing organization (CDMO) CoE located in the Alderley Park campus, the UK’s largest, single-site life science ecosystem, the Global Innovation CoE is geared to foster and accelerate life sciences innovation, with enhanced access to life sciences and biotechnology experts.
In alignment with the Company’s strategic areas of interest and commitment to driving innovation, the applicant selection process remains at the discretion of Charles River and the next cohort shortlist will be identified in conjunction with the upcoming Cell and Gene Therapy Summit, March 4, 2025, in
Our Experts: An Extension of Your Team
Bolstering its concept to cure capabilities, Charles River is proud to showcase a world-class team of scientific experts across the drug development continuum, providing broad experience and consultative advice.
With distinguished operational, quality, and regulatory experts including previous FDA, EMA, and MHRA advisors, the integrated network of Charles River professionals has supported thousands of IND and CTA submissions, reducing overall risk and setting programs up for success.
Meet with a Charles River expert at Advanced Therapies Week, January 20-23, 2025, in
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205936401/en/
Charles River Investor:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com
Charles River Media:
Amy Cianciaruso
Corporate Vice President,
Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com
Source: Charles River Laboratories International, Inc.
FAQ
What is the Charles River Incubator Program (CIP)?
How does the CIP differ from the CAP?
When will the next CIP cohort be shortlisted?
What expertise does Charles River offer through the CIP?
